Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 1.00 |
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 9/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | VEGFA | P15692 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | PDE5A | O76074 | 1/20 | 0.66 |
| ▸ | TNF | P01375 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PDE1A | P54750 | 1/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588637 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL13588642 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL7052450 | 0.83 | PDE4A (0.71) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL14045898 | 0.83 | PDE4A (0.71) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL9167416 | 0.83 | PDE4B (0.78) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL30822622 | 0.82 | PDE4A (0.82) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL19248302 | 0.82 | PDE4A (0.82) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL25724194 | 0.82 | PDE4A (0.82) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL9062953 | 0.82 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL3173894 | 0.82 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5362915-A | Inhibitors of enzymes/hydrolases; antiallergens, antiinflammatory agents | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1994-11-08 | — | — | US | claimed |
| EP-0523138-A1 | NOVEL DERIVATIVES OF PHENYL-CYCLOALKANES AND -CYCLOALKENES | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1993-01-20 | — | — | EP | claimed |
| WO-1991015451-A1 | NOVEL DERIVATIVES OF PHENYL-CYCLOALKANES AND -CYCLOALKENES | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1991-10-17 | — | — | WO | claimed |
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-12-03 | — | — | US | disclosed |
| US-7459479-B2 | Benzylated PDE4 inhibitors | BIOLIPOX AB (SE) | 2008-12-02 | — | — | US | disclosed |
| US-7446129-B2 | Benzylated PDE4 inhibitors | BIOLIPOX AB (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2007-09-06 | — | — | US | disclosed |
| EP-0642489-A1 | CYCLOPENTANE AND CYCLOPENTENE DERIVATIVES WITH ANTIALLERGIC ANTIINFLAMMATORY AND TUMOR NECROSIS FACTOR INHIBITING ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5362915-A | Inhibitors of enzymes/hydrolases; antiallergens, antiinflammatory agents | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1994-11-08 | — | — | US | disclosed |
| WO-1993007111-A1 | CYCLOPENTANE AND CYCLOPENTENE DERIVATIVES WITH ANTIALLERGIC ANTIINFLAMMATORY AND TUMOR NECROSIS FACTOR INHIBITING ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| EP-0523138-A1 | NOVEL DERIVATIVES OF PHENYL-CYCLOALKANES AND -CYCLOALKENES | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991015451-A1 | NOVEL DERIVATIVES OF PHENYL-CYCLOALKANES AND -CYCLOALKENES | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298864-A1 | Methods for Treating Mild Cognitive Impairment | CHAT, PSEN2, PSEN1 | PDE4B 335/4885PDE4A 282/4885PDE4C 402/4885 |
| US-20070208181-A1 | BENZYLATED PDE4 INHIBITORS | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.